1,072,439 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by Caisse de depot et placement du Quebec

Caisse de depot et placement du Quebec acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 1,072,439 shares of the biopharmaceutical company’s stock, valued at approximately $83,940,000.

A number of other hedge funds also recently bought and sold shares of HALO. Empowered Funds LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter worth approximately $755,000. Acadian Asset Management LLC acquired a new position in Halozyme Therapeutics in the 1st quarter worth approximately $195,000. Hsbc Holdings PLC boosted its stake in Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 5,448 shares during the period. EverSource Wealth Advisors LLC grew its position in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. raised its stake in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $106.92 on Friday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $109.66. The stock’s 50-day moving average is $86.27 and its two-hundred day moving average is $74.57. The firm has a market cap of $12.14 billion, a P/E ratio of 31.92, a PEG ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HALO. UBS Group restated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Morgan Stanley dropped their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. TD Cowen lifted their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, HC Wainwright increased their price target on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock worth $5,226,496 over the last ninety days. 2.50% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.